Michigan Prior Authorization Request Form For Prescription Drugs Instructions

Important: Please read all instructions below before completing FIS 2288.

Section 2212c of Public Act 218 of 1956, MCL 500.2212c, requires the use of a standard prior authorization form when a policy, certificate or contract requires prior authorization for prescription drug benefits.

A standard form, FIS 2288, is being made available by the Department of Insurance and Financial Services to simplify exchanges of information between prescribers and health insurers as part of the process of requesting prescription drug prior authorization. This form will be updated periodically and the form number and most recent revision date are displayed in the top left-hand corner.

- > This form is made available for use by prescribers to initiate a prior authorization request with the health insurer.
- > Prior authorization requests are defined as requests for pre-approval from an insurer for specified medications or quantities of medications before they are dispensed.
- ➤ "Prescriber" means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- ➤ "Prescription drug" means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- ➤ Pursuant to MCL 500.2212c, prescribers and insurers must comply with required timeframes pertaining to the processing of a prior authorization request. Insurers may request additional information or clarification needed to process a prior authorization request.
- ➤ The prior authorization is considered granted if the insurer fails to grant the request, deny the request, or require additional information of the prescriber within 72 hours after the date and time of submission of an expedited prior authorization request or within 15 days after the date and time of submission of a standard prior authorization request. If additional information is requested by an insurer, a prior authorization request is considered to have been granted by the insurer if the insurer fails to grant the request, deny the request, or otherwise respond to the request of the prescriber within 72 hours after the date and time of submission of the additional information for an expedited prior authorization request; or within 15 days after the date and time of submission of the additional information for standard prior authorization request.
- ➤ The prior authorization is considered void if the prescriber fails to submit the additional information within 5 days after the date and time of the original submission of a properly completed expedited prior authorization request or within 21 days after the date and time of the original submission of a properly completed standard prior authorization request.
- In order to designate a prior authorization request for expedited review, a prescriber must certify that applying the 15-day standard review period may seriously jeopardize the life and health of the patient or the patient's ability to regain maximum function.

PRESCRIBERS PLEASE SUBMIT THIS FORM TO THE PATIENT'S HEALTH PLAN ONLY. Please do not send to the department.

Only provide the physician's direct contact number and initials if you are requesting an Expedited Review Request.

Michigan Prior Authorization Request Form for Prescription Drugs

Fax: 858-790-7100

(PRESCRIBERS SUBMIT THIS FORM TO THE PATIENT'S HEALTH PLAN)

☐ Standard Review Request			
☐ Expedited Review Request: I had jeopardize the life or health of the part Physician's Direct Contact Phone N	atient or the patient's ability	to regain maximum fu	•
A) Reason for Request			
☐ Initial Authorization Request	☐ Renewal Request	☐ DAW	
B) Patient Demographics			
Is patient hospitalized: $\ \square$ Yes $\ \square$ N	0		
Patient Name:		DOB:	
Patient Health Plan ID:			
C) Pharmacy Insurance Plan ☐ Priority ☐ Magellan ☐ Blue C ☐ Total Health Care ☐ Blue Care	Cross Blue Shield of Michiga e Network □ HealthPlus o	n □ HAP ⊠ <u>P</u>	Iniversity of Michigan Prescription Drug Plan Ieridian Health Plar
D) Prescriber Information			
Prescriber Name:	NPI:	Specialty	/:
DEA (required for controlled substance			
Contact Name:			
E) Pharmacy Information (optional Pharmacy Name	•	elephone	
F) Requested Prescription Drug II	nformation		
Drug Name:		Strer	ngth:
Dosing Schedule:		Duration:	
Diagnosis (specific) with ICD#:			
Place of infusion / injection (if applica			
Facility Provider ID / NPI:			
Has the patient already started the m	edication? Yes	No If so, wher	1?

G)	history, curr	ent medication			ory of present illness, past medical sto support your request if you
Н)	Failed/Con	traindicated T	herapies		
Dru	ug Name	Strength	Dosing Schedule	Duration	Adverse Event/Specific Failure
l) 	relevant dia additional ir	ignostic labs, n	neasures of response to t may be necessary fo	o treatment, etc r review. Pleas	er information is necessary such as c.) Please refer to plan's website for se note that sending this form with od or adverse determination.
di de Pl	sclosed. A perefraud is provi	rson may be conded.	nmitting insurance fraud i	f false or deceptiv	rovided is true, complete and fully ve information with the intent to
	ate:				
			ption drug benefits.		prescribers when a patient's health plan
			*For Health Pla	•	
Re	quest Date: _				
				Denied: Denied By:	
				Reason for Γ	Denial:
	ditional Com	m onto:		reason for E	Cilial:





UNIVERSITY OF MICHIGAN – Netarsudil (Rhopressa), Netarsudil and Latanoprost (Rocklatan)

Some of the information needed to make a determination for coverage is not specifically requested on the Michigan Prior Authorization Request Form for Prescription Drugs. To avoid delays in reviewing your request, please make sure to include all of the following information.

Please answer the following questions for your patient:								
Does your patient have a diagnosis of open-angle glaucoma or ocular hypertension?	Y	N						
 2. Has your patient had an inadequate response to two or more of the following generic ophthalmic products? a. Latanoprost b. Bimatoprost c. Timolol d. Levobunolol e. Brimonidine f. Apraclonidine g. Dorzolamide h. Pilocarpine 	Y	N						

Revised August 9, 2019